Accuray Incorporated - Common Stock (ARAY)
Frequently Asked Questions About Accuray Incorporated - Common Stock (ARAY)
How can investors learn more about Accuray?
Investors can learn more about Accuray by visiting the company's official website, where they can access information about recent performance, product offerings, and corporate governance. Additionally, financial news platforms and stock market analysis tools provide updates and insights into Accuray's market position. Annual reports, earnings calls, and investor presentations offer valuable context on the company’s strategic direction and financial health.
How does Accuray address patient safety?
Accuray places a strong emphasis on patient safety through rigorous testing and validation processes for its radiation therapy systems. The company adheres to strict regulatory standards and conducts extensive clinical trials to ensure the efficacy and safety of its products. Additionally, Accuray provides comprehensive training for healthcare professionals to ensure that the systems are used correctly and effectively to minimize risks during treatment.
How does Accuray contribute to cancer treatment advancements?
Accuray contributes to cancer treatment advancements through continuous innovation and research in radiation therapy. The company invests in developing new technologies that improve precision, efficacy, and patient comfort during treatment. By collaborating with healthcare professionals and researchers, Accuray ensures its products incorporate the latest medical insights and technological advancements.
How does Accuray support patient care?
Accuray supports patient care through ongoing education and training programs for healthcare providers who utilize its technologies. The company provides resources that help clinicians optimize the use of its radiation therapy systems, ensuring that patients receive the most effective and compassionate care. Additionally, Accuray is committed to research and clinical studies that drive improvements in outcomes for cancer patients.
How has Accuray performed in the stock market?
Accuray is publicly traded on Nasdaq under the ticker symbol ARAY. Its stock performance has seen fluctuations common in the biomedical sector, influenced by factors such as quarterly earnings reports, product announcements, market conditions, and broader economic trends. Investors monitor the company closely for advancements in technology and market growth potential, which can impact stock price and investor sentiment.
What are Accuray's future plans?
Accuray's future plans include expanding its product offerings and enhancing existing technologies to improve cancer treatment efficacy. The company aims to enter new international markets, deepen collaborations, and continue its commitment to research and innovation. By focusing on these areas, Accuray hopes to increase its market share and enhance patient care globally.
What are some challenges faced by Accuray?
Like many companies in the medical technology sector, Accuray faces challenges such as regulatory hurdles, market competition, and the need to continually innovate to meet evolving customer needs. Additionally, the company must navigate the complexities of global healthcare systems and varying reimbursement policies that can affect sales and adoption of its products. However, it remains focused on addressing these challenges with strategic planning and adaptation.
What are the key products offered by Accuray?
Accuray’s key products include the CyberKnife System and the TomoTherapy System. The CyberKnife System is a robotic radiosurgery device that delivers highly targeted radiation therapy for tumors anywhere in the body, while the TomoTherapy System combines advanced, high-precision radiation delivery with imaging technology to treat cancer with great accuracy. Together, these products reflect Accuray's commitment to innovation in cancer care.
What does Accuray Incorporated do?
Accuray Incorporated is a leading innovator in the field of radiation oncology. The company designs and manufactures advanced radiation therapy systems, including the CyberKnife and TomoTherapy systems, aimed at providing accurate and effective cancer treatment. By incorporating cutting-edge technologies, Accuray enhances the precision of radiation delivery, which is essential for targeting tumors while minimizing damage to surrounding healthy tissue.
What is Accuray's commitment to innovation?
Accuray is deeply committed to innovation, continually seeking to advance its technology and improve cancer treatment methods. The company invests significantly in research and development to stay at the forefront of radiation therapy. By leveraging state-of-the-art technology and collaborating with medical experts, Accuray aims to develop solutions that enhance treatment accuracy and patient outcomes.
What is the significance of the CyberKnife system?
The CyberKnife system is significant because it represents one of the most advanced forms of non-invasive radiosurgery. Designed to treat tumors with high precision, it uses real-time imaging and robotic technology to adjust for patient movement during treatment. This capability allows clinicians to deliver lethal doses of radiation while sparing healthy surrounding tissues, which is critical in reducing side effects and improving patient outcomes.
What is TomoTherapy?
TomoTherapy is an advanced radiation therapy system developed by Accuray that combines the benefits of a linear accelerator and a CT scanner. This system allows for image-guided radiation therapy, enabling clinicians to deliver highly conformal doses of radiation while continuously adapting to any changes in tumor size or position. This innovative approach improves treatment accuracy and effectiveness.
What markets does Accuray serve?
Accuray serves multiple markets, focusing primarily on the oncology sector. The company operates globally, selling its products to healthcare facilities in North America, Europe, Asia-Pacific, and Latin America. Each market presents unique challenges and opportunities for cancer treatment, and Accuray tailors its approaches to meet the specific needs of healthcare providers in different regions.
What partnerships does Accuray have?
Accuray has formed strategic partnerships with various healthcare organizations, academic institutions, and technology companies to enhance its product offerings and research capabilities. These collaborations enable the sharing of knowledge, resources, and expertise, facilitating innovation in radiation therapy and improving treatment options for oncologists and patients alike.
What recent developments has Accuray announced?
Accuray regularly announces developments related to new product launches, technological advancements, and strategic partnerships. These announcements often showcase the company’s focus on enhancing the efficacy of its radiation therapy systems and expanding its presence in emerging markets. Recent developments may also include initiatives aimed at increasing access to cutting-edge cancer treatment globally.
What role does Accuray play in the fight against cancer?
Accuray plays a vital role in the fight against cancer by providing innovative radiation therapy solutions that offer precise and effective treatment options. Its technologies empower oncologists to deliver tailored therapies that meet the specific needs of patients, improving survival rates and quality of life. By advancing the capabilities of radiation therapy, Accuray contributes significantly to changing the landscape of cancer treatment.
When was Accuray Incorporated founded?
Accuray Incorporated was founded in 1990. The company originated from research at the Stanford University, where scientists were exploring innovative ways to improve radiation therapy for cancer patients. This early research laid the groundwork for what would become Accuray's flagship products and a commitment to advancing cancer treatment technology.
Where is Accuray Incorporated headquartered?
Accuray Incorporated is headquartered in Sunnyvale, California. This central location in Silicon Valley positions the company within a hub of technology and innovation, enabling it to collaborate with leading research institutions and access top talent in the fields of engineering and medicine.
Who are the primary customers of Accuray?
Accuray's primary customers include hospitals, cancer treatment centers, and integrated health systems worldwide. These institutions utilize Accuray's advanced radiation therapy systems to treat cancer patients, seeking to improve treatment options and outcomes through cutting-edge technology.
What is the current price of Accuray Incorporated - Common Stock?
The current price of Accuray Incorporated - Common Stock is 1.650
When was Accuray Incorporated - Common Stock last traded?
The last trade of Accuray Incorporated - Common Stock was at 4:00 pm EDT on October 2nd, 2025
What is the market capitalization of Accuray Incorporated - Common Stock?
The market capitalization of Accuray Incorporated - Common Stock is 157.99M
How many shares of Accuray Incorporated - Common Stock are outstanding?
Accuray Incorporated - Common Stock has 95.75M shares outstanding.